Equities Research Analysts’ Upgrades for October 5th (ACRV, ARI, BMEA, CBOE, DKNG, EL, HNVR, HUYA, KLAR, MNDY)

Equities Research Analysts’ upgrades for Monday, October 5th:

Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by analysts at Wall Street Zen from a sell rating to a hold rating.

Apollo Commercial Real Estate Finance (NYSE:ARI) was upgraded by analysts at Wall Street Zen from a sell rating to a hold rating.

Biomea Fusion (NASDAQ:BMEA) was upgraded by analysts at Wall Street Zen from a sell rating to a hold rating.

Cboe Global Markets (BATS:CBOE) was upgraded by analysts at TD Cowen from a hold rating to a buy rating. TD Cowen currently has $334.00 price target on the stock, up from their previous price target of $315.00.

DraftKings (NASDAQ:DKNG) was upgraded by analysts at Bank of America Corporation from a neutral rating to a buy rating. Bank of America Corporation currently has $27.00 target price on the stock.

Estee Lauder Companies (NYSE:EL) was upgraded by analysts at Barclays PLC from an equal weight rating to an overweight rating. Barclays PLC currently has $108.00 target price on the stock, up from their previous target price of $97.00.

Hanover Bancorp (NASDAQ:HNVR) was upgraded by analysts at Wall Street Zen from a hold rating to a buy rating.

HUYA (NYSE:HUYA) was upgraded by analysts at Wall Street Zen from a sell rating to a hold rating.

Klarna Group (NYSE:KLAR) was upgraded by analysts at Wall Street Zen from a sell rating to a hold rating.

monday.com (NASDAQ:MNDY) was upgraded by analysts at Wall Street Zen from a hold rating to a buy rating.

Grupo Aeroportuario Del Pacifico (NYSE:PAC) was upgraded by analysts at HSBC Holdings plc from a hold rating to a buy rating. HSBC Holdings plc currently has $277.00 target price on the stock.

PDS Biotechnology (NASDAQ:PDSB) was upgraded by analysts at Wall Street Zen from a sell rating to a hold rating.

Ryder System (NYSE:R) was upgraded by analysts at JPMorgan Chase & Co. from a neutral rating to an overweight rating. JPMorgan Chase & Co. currently has $298.00 target price on the stock, up from their previous target price of $296.00.

Rentokil Initial (NYSE:RTO) was upgraded by analysts at Stifel Nicolaus from a hold rating to a buy rating.

SBC Medical Group (NASDAQ:SBC) was upgraded by analysts at Wall Street Zen from a buy rating to a strong-buy rating.

Virtu Financial (NYSE:VIRT) was upgraded by analysts at JPMorgan Chase & Co. from a neutral rating to an overweight rating. They currently have $84.00 price target on the stock.